Genex Pharmaceutical IncOOTC GENX Stock Report

Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin and currently employs 86 full-time employees. The company went IPO on 2006-05-23. Genex was a start-up, Internet-based fulfillment company with offices in Vancouver, British Columbia, Canada. On June 8, 2004, Genex entered into a share purchase agreement with Tianjin Zhongjin Biology Development Co., Ltd. (Zhongjin). On June 17, 2004, the stock purchase made pursuant to the share purchase agreement was consummated and Zhongjin became a wholly owned subsidiary of Genex. Zhongjin engages in the business of producing and distributing Reconstituted Bone Xenograft (RBX), which is considered a medical device that accelerates bone healing. Zhongjin solely markets its medical devices to hospitals in China. Zhongjin distributes its medical devices to more than 500 hospitals in 30 provinces throughout China. Zhongjin also markets its medical devices to medical device customers in China that are not hospitals.